Cardiol Therapeutics

Oakville, Canada

Cardiol Therapeutics develops innovative cannabidiol medicines for heart disease.

$10.7M raised

Jan 2026

Post-IPO Equity

Biotechnology Life Science Nanotechnology

Top Investors

Raymond James AlbaCore Capital Canaccord Genuity Group Echelon Wealth Partners

Founder Contacts

30,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Cardiol Therapeutics

How much funding has Cardiol Therapeutics raised?

Cardiol Therapeutics has raised $10.7M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2026.

Who are Cardiol Therapeutics's investors?

Cardiol Therapeutics's investors include Raymond James, AlbaCore Capital, Canaccord Genuity Group, Echelon Wealth Partners.

Where is Cardiol Therapeutics headquartered?

Cardiol Therapeutics is headquartered in Oakville, Canada.

What does Cardiol Therapeutics do?

Cardiol Therapeutics develops innovative cannabidiol medicines for heart disease.

What stage is Cardiol Therapeutics at?

Cardiol Therapeutics is at the Post-IPO Equity stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 16, 2026.

MLA

"Cardiol Therapeutics — Funding & Investors." VCBacked, January 16, 2026, https://www.vcbacked.co/company/cardiol-therapeutics. Accessed July 3, 2026.

APA

VCBacked. (2026). Cardiol Therapeutics — Funding & Investors. Retrieved July 3, 2026, from https://www.vcbacked.co/company/cardiol-therapeutics

Wikipedia (cite web)

{{cite web |title=Cardiol Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/cardiol-therapeutics |website=VCBacked |access-date=July 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 16, 2026.